t fund, targeting companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, medical devices and other high technology opportunities that offer venture capital returns. The Fund focuses on seed and early stage companies, but also on pre-seed commercially viable academic projects.

The close collaboration between the fund, the technology transfer offices of the Life Sciences Centre Amsterdam and the Amsterdam Biomed Cluster, enables the fund to facilitate the transfer of technology to the private sector and to provide emerging technology companies and university researchers with vital seed funding and specialized financial and technical assistance. The fund started in 2007 and is now fully invested.